Sage Represents Trecondi® from Medac GmbH: Novel Product for Conditioning in AML and MDS Patients: O
Sage Group is working with medac GmbH who have developed Trecondi®, (Treosulfan), as a superior drug in conjunction with fludarabine prior to allogeneic hematopoetic stem cell transplantation (alloHSCT) in patients suffering from AML or MDS. medac completed a European clinical study of 570 patients (NCT 00822393). This randomized Phase III trial was designed as a non-inferiority study of a Trecondi® conditioning compared to a busulfan conditioning in adult patients with AML or MDS who were ineligible for standard myeloablative conditioning regimens. This study showed Trecondi® to be superior with respect to event-free-survival compared to busulfan in the selected patient population. medac h